The administration of ciglidazone, a thiazolidine-based PPARγ agonist, to colorectal cancer cells HT-29 reduces the expression of COX-2, suggesting that the activation of PPARγ suppresses the expression of COX-2 [28]. This evidence concerns the gene PPARG and colorectal cancer.